The KDM5C Knockout LoVo Polyclonal Cells are a CRISPR/Cas9-edited polyclonal human cell population engineered for disruption of the KDM5C gene. This product provides a heterogeneous knockout pool, offering a versatile tool for studying loss-of-function phenotypes without clonal bias. The polyclonal format preserves genetic diversity while ensuring effective target-gene disruption across the population, suitable for pooled screening and bulk analysis workflows.
The host cell line, LoVo, is a well-established human colorectal adenocarcinoma cell line originally isolated from a metastatic lymph node of a 56-year-old Caucasian male. These adherent, epithelial-like cells are widely used as a model system in colorectal cancer biology, drug response research, and intestinal epithelial barrier studies. Their genetic background and well-characterized signaling pathways make them particularly suitable for investigating tumorigenesis and metastatic mechanisms.
KDM5C encodes a histone lysine demethylase that specifically removes di- and trimethyl marks from histone H3 lysine 4 (H3K4me2/me3), functioning as a transcriptional repressor. It is a critical component of chromatin remodeling complexes, where it interacts with HDAC1/2, SIN3A, and the REST corepressor complex to silence neuronal genes in non-neuronal tissues. KDM5C activity is regulated by upstream factors including MYC and E2F transcription factors, and its demethylase function leads to transcriptional repression of cell cycle genes, differentiation regulators, and tumor suppressors. In colorectal cancer, KDM5C may modulate Wnt and Notch signaling outputs through chromatin-level regulation of target promoters.
In the LoVo colorectal cancer model, knockout of KDM5C is expected to increase global H3K4me2/me3 levels, resulting in derepression of genes normally silenced by this demethylase. This epigenetic perturbation may shift gene expression programs, potentially affecting proliferation, migration, invasion, and drug sensitivity. The polyclonal knockout population allows researchers to explore KDM5C function in a pathologically relevant, heterogeneous cancer cell context, better reflecting the complexity of tumor cell populations than monoclonal derivatives.
This knockout model is particularly suited for investigating epigenetic mechanisms in colorectal cancer progression, chromatin dynamics, and therapeutic target validation. Representative applications include chromatin immunoprecipitation (ChIP-qPCR) to assess histone modification changes at specific loci, Western blotting for H3K4me2/me3, RT-qPCR for downstream target expression, and functional assays such as MTT/Proliferation, transwell migration/invasion, and colony formation. Additionally, the cells can be used in drug sensitivity screens to evaluate KDM5C-dependent responses. For further details or to request a quote, please contact Ascent Research.
